FrancophonIA/ELRC3.0 huggingface dataset:
English: For more information about treatment with Xyrem, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Xyrem pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: Since the effective dose is close to the dose at which side effects become serious, increases in dose must be carried out strictly and under the supervision of a doctor specialised in the treatment of sleep disorders.
Croatian: Budući da je učinkovita doza blizu doze pri kojoj nuspojave postaju ozbiljne, povećanja doza moraju se provoditi isključivo i pod nadzorom liječnika specijaliziranog za liječenje poremećaja spavanja.
English: Xyrem also reduced excessive daytime sleepiness in patients who continued to take modafinil, as well as in those who took Xyrem alone.
Croatian: Xyrem je također smanjio prekomjernu dnevnu pospanost u bolesnika koji su nastavili uzimati modafinil kao i kod onih koji su uzimali sam Xyrem.
English: The active substance in Xyrem, sodium oxybate, is a central nervous system depressant.
Croatian: Djelatna tvar u lijeku Xyrem, natrijev oksibat, depresant je središnjeg živčanog sustava.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Xyrem.
Croatian: Objašnjava kako je Povjerenstvo za lijekove za primjenu kod ljudi (CHMP) ocijenilo lijek Xyrem da bi preporučilo njegovo odobrenje za stavljanje na tržište te uvjete za njegovu primjenu.
English: The other two studies (516 patients) examined the effects of Xyrem on excessive daytime sleepiness and other symptoms of narcolepsy, either taken alone or as an add-on to the patient's existing dose of modafinil (a stimulant medicine used to treat narcolepsy).
Croatian: Druga dva ispitivanja (516 bolesnika) proučavala su učinke lijeka Xyrem na prekomjernu dnevnu pospanost i druge simptome narkolepsije ili kad se lijek uzimao sam ili kao dodatak postojećoj bolesnikovoj dozi modafinila (stimulirajući lijek koji se koristi za liječenje narkolepsije).
English: What is Xyrem?
Croatian: Što je Xyrem?
English: The first study (136 patients) examined the effects of Xyrem on the number of cataplexy attacks over four weeks of treatment.
Croatian: Prvo ispitivanje (136 bolesnika) proučavalo je učinke lijeka Xyrem na broj napadaja katapleksije tijekom 4 tjedna liječenja.
English: Xyrem is given at a dose of 4.5 to 9 g per day in two equally divided doses.
Croatian: Xyrem se daje u dozi od 4,5 do 9 g po danu u dvije jednake doze.
English: The dose of Xyrem should also be reduced by a fifth if patients are taking the medicine valproate for another condition at the same time as they are taking Xyrem.
Croatian: Dozu lijeka Xyrem također treba smanjiti za petinu ako bolesnici uzimaju valproat zbog drugih stanja u isto vrijeme kad i Xyrem.
English: What is the risk associated with Xyrem?
Croatian: Koji su rizici povezani s lijekom Xyrem?
English: The most common side effects with Xyrem (seen in more than 1 patient in 10) are dizziness, headache and nausea (feeling sick).
Croatian: Najčešće nuspojave lijeka Xyrem (kod više od 1 na 10 osoba) su vrtoglavica, glavobolja i mučnina.
English: In all of the studies, Xyrem was given at a daily dose between 3 and 9 g and was compared with placebo (a dummy treatment).
Croatian: U svim ispitivanjima Xyrem se davao pri dnevnoj dozi između 3 i 9 g te je uspoređen s placebom (prividnim liječenjem).
English: The second study, including 56 patients who had been taking Xyrem for at least six months, compared the effects of continuing to take Xyrem at the same dose as before, with the effects of switching to placebo.
Croatian: Drugo ispitivanje koje je uključivalo 56 bolesnika koji su uzimali Xyrem tijekom najmanje 6 mjeseci, uspoređivalo je učinke uzimanja lijeka Xyrem u istoj dozi kao i prije, s učincima prebacivanja na placebo.
English: Patients are also advised against taking alcohol while on treatment with Xyrem.
Croatian: Bolesnicima se također savjetuje da ne uzimaju alkohol dok se liječe lijekom Xyrem.
English: The second study showed that Xyrem continued to prevent cataplexy attacks after long-term treatment: there was no change over two weeks in the number of attacks in the patients continuing to take Xyrem, compared to an increase of 21.0 attacks in those switching to placebo.
Croatian: Drugo je ispitivanje pokazalo da je Xyrem nastavio sprječavati napadaje katapleksije nakon dugotrajnog liječenja: nije bilo promjene tijekom dva tjedna u broju napadaja kod bolesnika koji su nastavili uzimati Xyrem, u usporedbi s porastom od 21, 0 napadaja u onih koji su se prebacili na placebo.
English: The Committee recommended that Xyrem be given marketing authorisation.
Croatian: Povjerenstvo je preporučilo izdavanje odobrenja za stavljanje u promet lijeka Xyrem.
English: Why has Xyrem been approved?
Croatian: Zašto je lijek Xyrem odobren?
English: Because sodium oxybate can be abused, doctors must carefully monitor patients using Xyrem.
Croatian: S obzirom na to da se natrijev oksibat može zloupotrijebiti, liječnici moraju pomno nadzirati bolesnike koji uzimaju Xyrem.
English: Xyrem treatment should be started and given under the guidance of a doctor who has experience in the treatment of sleep disorders.
Croatian: Liječenje lijekom Xyrem treba se započeti i davati pod nadzorom liječnika iskusnom u liječenju poremećaja sna.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Xyrem, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana u sažetak opisa svojstava lijeka kao i u uputu o lijeku, za lijek Xyrem uključene su sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: The CHMP decided that Xyrem's benefits are greater than its risks.
Croatian: CHMP je odlučio da koristi lijeka Xyrem nadmašuju s njim povezane rizike.
English: How has Xyrem been studied?
Croatian: Kako je Xyrem proučavan?
English: The maximum daily dose is 9 g. Patients should usually start with two doses of 2.25 g (4.5 ml) per day.
Croatian: Bolesnici obično trebaju početi liječenje s dvije doze od 2,25 g (4,5 ml) po danu.
English: What benefit has Xyrem shown during the studies?
Croatian: Koje su koristi lijeka Xyrem dokazane u ispitivanjima?
English: Because sodium oxybate can be abused, doctors should check for a history of or susceptibility to drug abuse before treatment, and monitor for misuse and abuse during treatment.
Croatian: S obzirom na to da postoji mogućnost od zloupotrebe natrijeva oksibata, liječnici moraju provjeriti anamnezu podložnosti na zloupotrebu lijeka prije liječenja i nadzirati bolesnika tijekom liječenja u slučaju pojave pogrešne upotrebe i zloupotrebe.
English: What is Xyrem used for?
Croatian: Za što se Xyrem koristi?
English: The starting dose should be halved in patients who have problems with their liver.
Croatian: Kod bolesnika koji imaju problema s jetrom početnu dozu treba prepoloviti.
English: How is Xyrem used?
Croatian: Kako se Xyrem koristi?
English: For the full list of all side effects reported with Xyrem, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Xyrem potražite u uputi o lijeku.
English: How does Xyrem work?
Croatian: Kako djeluje Xyrem?
English: In children, the dose depends on body weight and height.
Croatian: U djece doza ovisi o tjelesnoj težini i visini.
English: This summary was last updated in 07-2017.
Croatian: Sažetak je posljednji put ažuriran u 07. 2017.
English: The full EPAR for Kaletra can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Cjeloviti EPAR za lijek Kaletra nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The capsules and liquid must be taken with food, but the tablets can be taken with or without food.
Croatian: Kapsule i tekućina moraju se uzimati s hranom, ali tablete se mogu uzimati s hranom ili bez nje.
English: The medicine is taken once or twice daily in adults, and the dose depends on the type of virus the patient is infected with.
Croatian: Odrasle osobe uzimaju lijek jednom ili dvaput dnevno, a doza ovisi o vrsti virusa kojim je bolesnik zaražen.
English: This is a summary of the European public assessment report (EPAR) for Kaletra.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Kaletra.
English: What measures are being taken to ensure the safe and effective use of Kaletra?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Kaletra?
English: The medicine is also well tolerated and its side effects are manageable.
Croatian: Lijek se također dobro podnosi, a njegove nuspojave mogu se kontrolirati.
English: HIV is the virus that causes acquired immune deficiency syndrome (AIDS).
Croatian: HIV je virus koji uzrokuje sindrom stečene imunodeficijencije (SIDA).
English: Other information about Kaletra
Croatian: Ostale informacije o lijeku Kaletra
English: Kaletra does not cure HIV infection or AIDS, but it may hold off damage to the immune system, and the development of infections and diseases associated with AIDS.
Croatian: Kaletra ne liječi infekciju HIV-om ili AIDS, ali može odgoditi oštećenje imunosnog sustava i razvoj infekcija i bolesti povezanih sa AIDS-om.
English: When the enzyme is blocked, the virus does not reproduce normally slowing down its multiplication in the body.
Croatian: Kada je taj enzim blokiran, virus se ne razmnožava na uobičajen način, što usporava njegovu stopu replikacije u tijelu.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Kaletra on 20 March 2001.
Croatian: Europska komisija izdala je odobrenje za stavljanje lijeka Kaletra u promet koje vrijedi na prostoru Europske unije od 20. ožujka 2001.
English: What is Kaletra and what is it used for?
Croatian: Što je Kaletra i za što se koristi?
English: The European Medicines Agency (EMA) therefore concluded that the benefits of Kaletra outweigh its risks and recommended that it be given marketing authorisation in the EU.
Croatian: Europska agencija za lijekove (EMA) stoga je zaključila da koristi lijeka Kaletra nadmašuju s njim povezane rizike te je preporučila davanje odobrenja za stavljanje lijeka u promet.
English: Kaletra is available as tablets, capsules and oral liquid.
Croatian: Lijek Kaletra dostupan je u obliku tableta, kapsula i oralne tekućine.
English: It is not intended to provide practical advice on how to use Kaletra.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Kaletra.
English: Both active substances in Kaletra are protease inhibitors: they block an enzyme called protease that is involved in the reproduction of HIV.
Croatian: Obje djelatne tvari u lijeku Kaletra su inhibitori proteaze: one blokiraju enzim nazvan proteaza koji je uključen u reprodukciju HIV-a.
English: Kaletra contains two active substances, lopinavir and ritonavir.
Croatian: Kaletra sadržava dvije djelatne tvari, lopinavir i ritonavir.
English: Studies have shown that Kaletra is effective at reducing viral load (the amount of virus found in the blood) to very low levels (below 400 copies/ml).
Croatian: Ispitivanja su pokazala da je lijek Kaletra djelotvoran u smanjivanju virusnog opterećenja (količina virusa u krvi) na vrlo niske razine (manje od 400 kopija/ml).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kaletra have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Kaletra nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: In Kaletra, lopinavir provides the activity against the virus while ritonavir mainly works as a ‘booster' to slow down the rate at which lopinavir is broken down by the liver.
Croatian: U lijeku Kaletra lopinavir omogućuje protuvirusno djelovanje, a ritonavir uglavnom djeluje kao „pojačivač” za usporavanje stope kojom jetra razgrađuje lopinavir.
English: What are the risks associated with Kaletra?
Croatian: Koji su rizici povezani s lijekom Kaletra?
English: The most common side effects with Kaletra in adults (seen in more than 1 patient in 10) are upper respiratory tract infection (colds), nausea (feeling sick) and diarrhoea.
Croatian: Najčešće nuspojave lijeka Kaletra u odraslih osoba (uočene u više od 1 na 10 osoba) jesu infekcije gornjeg dišnog sustava (prehlade), mučnina (slabost) i proljev.
English: Kaletra must not be used by patients with severe liver disease or by patients who are taking St John's wort (a herbal preparation used to treat depression) or medicines that are broken down in the same way as Kaletra and are harmful at high levels in the blood.
Croatian: Lijek Kaletra ne smije se primjenjivati u bolesnika s teškim oštećenjem jetre ili bolesnika koji uzimaju gospinu travu (biljni pripravak za liječenje depresije) ili lijekove koji se razgrađuju na isti način kao Kaletra i koji su štetni u visokim koncentracijama u krvi.
English: Kaletra can only be obtained with a prescription and should be prescribed by a doctor with experience treating HIV infection.
Croatian: Lijek Kaletra izdaje se samo na recept, a treba ga propisati liječnik s iskustvom u liječenju infekcije HIV-om.
English: Kaletra is effective at reducing HIV viral loads to below 400 copies/ml in the majority of adults and children from 14 days of age.
Croatian: Lijek Kaletra djelotvoran je u smanjivanju opterećenja virusom HIV-a ispod 400 kopija/ml u većine odraslih osoba i djece starije od 14 dana.
English: Kaletra is an HIV medicine used in combination with other medicines to treat adults and children from over 14 days of age who are infected with HIV-1.
Croatian: Kaletra je lijek za liječenje HIV-a koji se primjenjuje u kombinaciji s drugim lijekovima za liječenje odraslih osoba i djece starije od 14 zaražene virusom HIV-1.
English: Studies in children from 14 days of age showed between 71% and 85% of patients having very low levels of the virus after 48 weeks of treatment with Kaletra.
Croatian: Ispitivanja na djeci starijoj od 14 dana pokazala su da je između 71 % i 85 % bolesnika imalo vrlo niske razine virusa nakon 48 tjedana liječenja lijekom Kaletra.
English: Why is Kaletra approved?
Croatian: Zašto je lijek Kaletra odobren?
English: In one study of adults who had not been treated for HIV before, 79% of the patients taking Kaletra (259 out of 326) had very low levels of the virus after 24 weeks, compared with 71% of the patients taking nelfinavir (233 out of 327).
Croatian: U jednom ispitivanju na odraslim osobama koje nisu prethodno liječene od infekcije virusom HIV-a, 79 % bolesnika koji su uzimali lijek Kaletra (259 od 326) imalo je vrlo niske razine virusa nakon 24 tjedna u usporedbi sa 71 % bolesnika koji su uzimali nelfinavir (233 od 327).
English: A second adult study in patients who had previously taken a protease inhibitor, 73% of the patients taking Kaletra (43 out of 59) had very low levels of the virus after 16 weeks, compared with 54% of the patients taking the comparator medicines (32 out of 59).
Croatian: U drugom ispitivanju koje je obuhvaćalo odrasle osobe koje su prethodno uzimale inhibitor proteaze, 73 % bolesnika koji su uzimali lijek Kaletra (43 od 59) imalo je vrlo niske razine virusa nakon 16 tjedna u usporedbi s 54 % bolesnika koji su uzimali usporedne lijekove (32 od 59).
English: For practical information about using Kaletra, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Kaletra bolesnici trebaju pročitati u uputi o lijeku, odnosno trebaju se obratiti svojem liječniku ili ljekarniku.
English: What benefits of Kaletra have been shown in studies?
Croatian: Koje su koristi lijeka Kaletra dokazane u ispitivanjima?
English: For more information about treatment with Kaletra, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Kaletra pročitajte u uputi o lijeku (također dio EPAR-a) odnosno obratite se svojem liječniku ili ljekarniku.
English: How is Kaletra used?
Croatian: Kako se Kaletra koristi?
English: For the full list of all side effects reported with Kaletra, see the package leaflet.
Croatian: Potpuni popis svih nuspojava zabilježenih pri primjeni lijeka Kaletra potražite u uputi o lijeku.
English: How does Kaletra work?
Croatian: Kako djeluje Kaletra?
English: Immediate Packaging Pack size
Croatian: Unutarnje pakovanje Veličina pakovanja
English: Wash hands after use.
Croatian: Nakon uporabe operite ruke.
English: Date of first authorisation: 09/01/2019
Croatian: Datum prvog odobrenja: 09/01/2019
English: 2.5 to 4 > 4 to 6 > 6 to 8
Croatian: 2,5 do 4 > 4 do 6 > 6 do 8
English: The renal lesions were still present at 28 days after the end of treatment.
Croatian: Bubrežne lezije još su uvijek bile prisutne 28 dana nakon završetka primjene.
English: The tablet can be divided into halves.
Croatian: Tableta se može podijeliti na dvije polovice.
English: In dogs, the plasma protein binding is > 98%.
Croatian: U pasa, vezanje za proteine plazme je > 98%.
English: As the safety of the product has not been established in the target species, the use of the product is not recommended during pregnancy, lactation and breeding animals.
Croatian: Budući da neškodljivost proizvoda nije utvrđena u ciljnih vrsta, upotreba proizvoda ne preporučuje se tijekom trudnoće, laktacije i u rasplodnih životinja.
English: All strengths are available in the following pack sizes:
Croatian: Sve jačine dostupne su u sljedećim veličinama pakovanja:
English: Oral use.
Croatian: Oralna upotreba.
English: If the tablet is not spontaneously taken by the dog, it can also be given with food or directly into the mouth.
Croatian: Ako pas ne uzima spontano tabletu, može mu se dati u hrani ili izravno u usta.
English: Consequently, the medicinal product can be administered with or without food.
Croatian: Stoga se ovaj medicinski proizvod može primjenjivati s hranom ili bez nje.
English: Interaction with other medicinal products and other forms of interaction:
Croatian: Interakcija s drugim medicinskim proizvodima i drugi oblici interakcija:
English: Each blister contains 10 tablets and is packed in a cardboard box.
Croatian: Svaki blister sadrži 10 tableta i pakiran je u kartonsku kutiju.
English: As torasemide increases thirst, dogs should have free access to fresh water.
Croatian: Budući da torasemid povećava žeđ, psi trebaju imati slobodan pristup svježoj vodi.
English: After this period, the dose should be reduced to the maintenance dose and the dog should be evaluated by the veterinarian in a few days.
Croatian: Nakon tog perioda, dozu treba smanjiti na dozu održavanja i nakon nekoliko dana veterinar treba pregledati psa.
English: An increase in albumin serum concentration was observed.
Croatian: Primijećeno je povećanje koncentracije serumskog albumina.
English: The causative role of changes in plasma electrolyte values cannot be excluded.
Croatian: Uzročna uloga promjene vrijednosti elektrolita u plazmi ne može se isključiti.
English: Do not use in cases of dehydration, hypovolaemia or hypotension.
Croatian: Ne primjenjivati u slučajevima dehidracije, hipovolemije ili hipotenzije.
English: Two metabolites (a dealkylated and a hydroxylated metabolite) have been identified in urine.
Croatian: Dva metabolita (metabolit dealkilacije i hidroksilni metabolit) identificirani su u urinu.
English: If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.
Croatian: Ako primijetite bilo koju nuspojavu, čak i one koje nisu navedene u ovoj uputi o VMP ili mislite da veterinarsko-medicinski proizvod ne djeluje, molimo obavijestite svog veterinara.
English: Ceva Santé Animale ZI Très le Bois 22600 Loudéac France
Croatian: Ceva Santé Animale ZI Très le Bois 22600 Loudéac Francuska
English: A large proportion of the dose (about 60%) is excreted in the urine as unchanged parent substance.
Croatian: Velik dio doze (oko 60%) izlučuje se urinom kao nepromijenjena izvorna tvar.
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Croatian: Detaljne informacije o ovom veterinarsko-medicinskom proizvodu dostupne su na web-stranici Europske agencije za lijekove (http://www.ema.europa.eu/).
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Blister
Croatian: OSNOVNI PODACI KOJI SE MORAJU NALAZITI NA BLISTERIMA ILI TRAKAMA Blister
English: Overdose (symptoms, emergency procedures, antidotes):
Croatian: Predoziranje (simptomi, postupci u hitnim slučajevima, antidoti):
English: EXP {month/year}
Croatian: ROK VALJANOSTI EXP mjesec/godina
English: These lesions may most likely be considered as a result of the pharmacodynamic effect (diuresis) and were not associated with evidence of glomerulosclerosis or interstitial fibrosis.
Croatian: Te se lezije najvjerojatnije mogu smatrati rezultatom farmakodinamičkog učinka (diureze) i nisu bile povezane s pokazateljima glomeruloskleroze ili intersticijske fibroze.
English: This veterinary medicinal product may cause hypersensitivity (allergic) reactions in persons that are sensitized to torasemide.
Croatian: Ovaj veterinarsko-medicinski proizvod može prouzročiti preosjetljivost (alergijsku reakciju) kod osoba koje su osjetljive na torasemid.
English: Blister pack of polyamide/aluminium/PVC, thermo-sealed by an aluminium foil (each blister contains 10 tablets) and packaged in a cardboard box.
Croatian: Blister pakovanje od poliamida/aluminija/PVC-a, toplinski zabrtvljeno aluminijskom folijom (svaki blister sadrži 10 tableta), u kartonskoj kutiji.
English: Laboratory studies in rats and rabbits have shown foetotoxicity at maternotoxic doses.
Croatian: Laboratorijska ispitivanja na štakorima i zečevima pokazala su fetotoksičnost lijeka pri maternotoksičnim dozama.
English: Cardboard box (90 tablets)
Croatian: Kartonska kutija (90 tableta)
English: All strengths are available in pack sizes of 30 or 90 tablets.
Croatian: Sve jačine dostupne su u veličinama pakovanja od 30 ili 90 tableta.
English: Bodyweight (kg)
Croatian: Tjelesna težina psa (kg)
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Croatian: Detaljne informacije o ovom veterinarsko-medicinskom proizvodu dostupne su na web-stranici Europske agencije za lijekove http://www.ema.europa.eu.
English: EU/2/18/232/001 (30 tablets 1 mg) EU/2/18/232/002 (90 tablets 1 mg) EU/2/18/232/003 (30 tablets 2 mg) EU/2/18/232/004 (90 tablets 2 mg) EU/2/18/232/005 (30 tablets 4 mg) EU/2/18/232/006 (90 tablets 4 mg)
Croatian: EU/2/18/232/001 (30 tableta od 1 mg) EU/2/18/232/002 (90 tableta od 1 mg) EU/2/18/232/003 (30 tableta od 2 mg) EU/2/18/232/004 (90 tableta od 2 mg) EU/2/18/232/005 (30 tableta od 4 mg) EU/2/18/232/006 (90 tableta od 4 mg)
English: +-2Cl cotransporter localised in the luminal membrane (urine side) and blocks the active reabsorption of sodium and chloride.
Croatian: +-2Cl lokaliziranim u luminalnoj membrani (strana urina) i blokira aktivnu reapsorpciju natrija i klorida.
English: Torasemide may increase the risk of sulfonamide allergy.
Croatian: Torasemid može povećati rizik od alergije na sulfonamide.
English: This veterinary medicinal product may cause increased urination, thirst and/or gastrointestinal disturbances and/or hypotension and/or dehydration if ingested.
Croatian: Ovaj veterinarsko-medicinski proizvod može prouzročiti pojačano mokrenje, žeđ i/ili gastrointestinalne smetnje i/ili hipotenziju i/ili dehidraciju ako se proguta.